Part of The Mesothelioma Center. Contact Us
Mesothelioma-Line.com.
Journal Articles on Mesothelioma: Cancer Information for Patients and Families

Journal Articles on Mesothelioma: 'EGFR' Category

Epidermal growth factor receptor (also known as ErbB1, ErbB, oncogene ErbB, and HER1). A protein found on the surface of cells to which epidermal growth factor (EGF) binds; when this happens, the enzyme tyrosine kinase is activated, triggering reactions that cause the cells to grow and multiply. EGFR is found at abnormally high levels on the surface of many types of cancer cells.

EGFR news feed.

Newer Headlines »

July 13th, 2005. Therapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural Mesothelioma

Our findings suggest that ErbB1 alone is a therapeutic target for the minority of mesotheliomas and that combining ErbB1 inhibitors with signal transduction inhibitors in mesothelioma will enhance their effectiveness. Furthermore, combinations of growth factor and signal transduction inhibitors may be needed to inhibit the growth of the majority of MPM cell lines, and therefore patients with MPM.
Posted in EGFR, Full Archive, Pleural, Signal Transduction Inhibitors, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »

May 1st, 2005. Therapeutic options in malignant pleural mesothelioma

Radiotherapy may be applied in case of local tumour growth. The individual therapeutic decision will depend on tumour stage, concomitant diseases, performance status, and on the patient's preference.
Posted in Cisplatin (Platinol ®), Determining Efficacy, EGFR, Extrapleural Pneumonectomy (EPP), Full Archive, Pemetrexed (Alimta), Pleural, Pneumonectomy, Radiation, Surgery, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »

May 1st, 2005. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro

Conclusions: Epidermal growth factor receptor tyrosine kinase inhibitor PD153035 significantly inhibited motility and invasion in malignant pleural mesothelioma cells in vitro, regardless of their epidermal growth factor receptor expression levels. Inhibition of epidermal growth factor receptor-dependent signaling might be a useful strategy to diminish malignant pleural mesothelioma recurrence after aggressive cytoreductive surgery.
Posted in EGFR, Full Archive, Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
Newer Headlines »
Goldberg, Persky & White, P.C. Mesothelioma Lawyers